Search results
Results from the WOW.Com Content Network
The polysaccharide vaccines, while effective in healthy adults, are not effective in children less than two years old or those with poor immune function. [1] [4] These vaccines are generally safe. [1] With the conjugate vaccine about 10% of babies develop redness at the site of injection, fever, or change in sleep. [1] Severe allergies are very ...
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
CORRECTION: (Oct. 24, 2024, 3:34 p.m. ET) Because of an editing error, a previous version of this article misstated the recommended dose for the pneumonia vaccine. It is intended as a single dose ...
Part D covers most preventive vaccinations, while Part B covers a few specific vaccines, like the pneumonia vaccine. Medicare Advantage plans, sometimes called Part C, also cover the pneumonia ...
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, or variations of the bacteria, that the shot targeted in a variety of adult populations across studies.
The pneumococcal polysaccharide vaccine is widely used in high-risk adults. [4] First used in 1945, the tetravalent vaccine was not widely distributed, since its deployment coincided with the discovery of penicillin. [5] In the 1970s, Robert Austrian championed the manufacture and distribution of a 14-valent pneumococcal polysaccharide vaccine.
“A serogroup B meningococcal (MenB) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age. (Category B)” [6] The motion was passed, 14 to 1.